Improvement of impaired albumin binding capacity in acute‐on‐chronic liver failure by albumin dialysis

Sebastian Klammt, Steffen R. Mitzner, Jan Stange, Jan Loock, Uwe Heemann, Jörg Emmrich, Emil C. Reisinger, Reinhard Schmidt – 28 August 2008 – Extracorporeal albumin dialysis (ECAD) enables the elimination of albumin bound substances and is used as artificial liver support system. Albumin binding function for the benzodiazepine binding site specific marker Dansylsarcosine was estimated in plasma samples of 22 patients with cirrhosis and hyperbilirubinaemia (ECAD: n = 12; control: n = 10) during a period of 30 days in a randomized controlled clinical ECAD trial.

Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5‐fluorouracil in mice

Tamotsu Sagawa, Yasuyuki Yamada, Minoru Takahashi, Yasushi Sato, Masayoshi Kobune, Rishu Takimoto, Junki Fukaura, Satoshi Iyama, Tsutomu Sato, Koji Miyanishi, Takuya Matsunaga, Tetsuji Takayama, Junji Kato, Katsunori Sasaki, Hirofumi Hamada, Yoshiro Niitsu – 28 August 2008 – Although conditionally replicable adenovirus (CRAd) has been used in the clinical treatment of hepatocellular carcinoma (HCC), it suffers from the inherent drawback of having relatively low antitumor activity. Here, we have sought to overcome this drawback.

Subscribe to